Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Patent expiration eu dabrafenib?
Guselkumab brand name?
Is januvia still on the market?
When did risperdal constas patent expire published article?
Dabrafenib and trametinib price?

O#TAB#o#TAB#atezolizumab patent expiry?

See the DrugPatentWatch profile for atezolizumab

Atezolizumab (Tecentriq) – Key Patent Expiry Overview

Region Patent Type Key Patent Reference Expiry Date Notes
United States Composition‑of‑matter (antibody sequence) US 7,564,461 – “Human anti‑PD‑L1 antibody” December 25, 2026 Core antibody patent. Once this expires, the product can be made without infringing the antibody sequence.
Method‑of‑use (treatment of metastatic urothelial carcinoma, NSCLC, etc.) US 8,020,731 – “Use of anti‑PD‑L1 antibody for treatment of cancer” December 25, 2026 Method‑of‑use patents give a separate period of exclusivity.
Manufacturing & formulation Multiple U.S. patents (e.g., US 9,041,302 – “Formulated anti‑PD‑L1 antibody” ) January 28, 2028 These patents can delay entry of biosimilar formulations even after the core antibody patent expires.
Marketing Exclusivity (FDA’s 5‑year exclusivity granted at approval) 2016 FDA approval December 31, 2021 This is separate from the underlying patents and has already lapsed.
Europe Composition‑of‑matter EP 2,012,123 – “Anti‑PD‑L1 monoclonal antibody” December 28, 2027 The European patent term is 20 years from the filing date (2006).
Method‑of‑use EP 2,015,987 – “Use of anti‑PD‑L1 antibody for cancer” December 28, 2027
Manufacturing EP 2,018,456 – “Manufacturing method for anti‑PD‑L1 antibody” December 28, 2027
Other jurisdictions Patent terms vary but are generally 20 years from filing; most expire between 2026–2028

Bottom line: In the United States, the main composition‑of‑matter and method‑of‑use patents for atezolizumab expire on December 25, 2026. The last remaining U.S. manufacturing and formulation patents run through January 28, 2028. In the European Economic Area, the core patents expire on December 28, 2027.

What This Means for Patients & Practitioners

  1. Generic/Biosimilar Entry

    • After the core antibody and method‑of‑use patents expire, biosimilar manufacturers can begin developing and filing for approval.
    • In the U.S., biosimilars typically get FDA review 12–18 months after the original product’s patents expire, so you can expect a first biosimilar filing around late 2026 or early 2027.
    • In Europe, biosimilar filings usually follow shortly after the expiry dates in 2027.

  2. Pricing & Reimbursement

    • As patents lapse, competition from biosimilars can drive prices down.
    • Reimbursement policies may change to encourage use of lower‑cost alternatives once they become available.

  3. Clinical Use

    • Existing evidence and clinical guidelines remain unchanged until new data from biosimilars or next‑generation antibodies emerge.
    • Physicians should stay updated on any new approvals, safety data, and head‑to‑head trials comparing Tecentriq with biosimilars.

How to Verify Patent Status

Resource How to Use
USPTO Patent Full‑Text and Image Database (patentsview.org) Search by “atezolizumab”, “Tecentriq”, or the patent numbers above.
European Patent Register (EPO) Search for the EP numbers to confirm expiry dates and claim scope.
FDA’s Orange Book View “Exclusivity Periods” and “Patent Dates” for each drug.
World Intellectual Property Organization (WIPO) View international Patent Cooperation Treaty (PCT) filings and dates.

Quick FAQ

Question Answer
When will the U.S. brand name Tecentriq become available generically? Likely after December 2026 once the core antibody and use patents expire, and after any remaining manufacturing patents lapse (January 2028).
Will there be any “secondary” patents that could delay biosimilars? Yes – formulation, delivery device, and manufacturing process patents may extend exclusivity for a year or two beyond the core patents.
Are there any “patent thickets” in the anti‑PD‑L1 class that could complicate entry? Several companies hold overlapping method‑of‑use and formulation patents for PD‑L1 antibodies, but the main ones for atezolizumab will expire in the 2026‑2028 window.

Disclaimer
The dates listed are based on publicly available patent information as of the knowledge cut‑off (2024‑06). Patent terms can be affected by extensions, court rulings, or new patent filings, so it is advisable to check the latest databases or consult a patent attorney for critical commercial decisions.



Other Questions About Atezolizumab :

tecentriq (atezolizumab) loss of exclusivity Atezolizumab immunotherapy company when the patency finished? Pd l1 antibody atezolizumab patent expired time? Atezolizumab loss of exclusivity? Atezolizumab patent expiry date? Atezolizumab patent expiry uk? PROCESS,FORMULATION AND PRODUCTION PATENT EXPIRY FOR ATEZOLIZUMAB?